In vitro activity of Ceftazidime–Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019

Bakthavatchalam, Yamuna Devi; Routray, Abhisek; Mane, Akshata; Kamat, Shweta; Gupta, Anu; Bari, Anurag Kumar; Rohit, Anusha; Poojary, Aruna; Mukherjee, Dip Narayan; Sethuraman, Nandini; Munshi, Nita; Shah, Sweta; Veeraraghavan, Balaji; Gupta, Yogesh

doi:10.1016/j.diagmicrobio.2022.115652

Cited by 28 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An overall susceptibility rate of over 70% was reported among K. pneumoniae and E. coli isolates. Around 51% of carbapenem-resistant (CR)- K. pneumoniae and 24% of CR- E. coli isolates were found to be susceptible to ceftazidime-avibactam [ 5 ].…”

Section: Reviewmentioning

confidence: 99%

“…Tigecycline and colistin face challenges such as low plasma concentration and nephrotoxicity, respectively [ 5 , 65 , 66 ]. Colistin may be limited in its use due to its narrow therapeutic index, challenges with dose optimization, poor lung penetration, nephrotoxicity, and emerging antimicrobial resistance [ 61 , 65 , 67 ].…”

Section: Reviewmentioning

confidence: 99%

“…The carbapenem resistance in Enterobacterales is driven by carbapenemases such as New Delhi metallo-β-lactamase (NDM), and Oxacillinase-48 like (OXA-48-like) VIM, IMP and KPC [ 3 , 4 ]. In India, high carbapenem resistance among Enterobacterales has been reported by the Indian Council of Medical Research (ICMR) with resistance rates up to 30% for Escherichia coli and 50% for Klebsiella pneumoniae [ 5 ]. OXA-48-like gene was identified in 52% of the carbapenem-resistant (CR)- K. pneumoniae isolates while 20% isolates possessed NDM gene and 27% isolates had both NDM with OXA-48-like gene.…”

Section: Introductionmentioning

confidence: 99%

“…OXA-48-like gene was identified in 52% of the carbapenem-resistant (CR)- K. pneumoniae isolates while 20% isolates possessed NDM gene and 27% isolates had both NDM with OXA-48-like gene. However, in carbapenem-resistant (CR)- E. coli , NDM was identified in 68% of isolates followed by OXA-48-like in 24% isolates and 8% isolates carried both NDM with OXA-48-like gene [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…Colistin and tigecycline have been used as first-line therapy for managing infections caused by CREs [ 8 ]. However, tigecycline does not attain the required plasma concentrations, and hence may not be used for treating bloodstream infections [ 5 ]. Colistin has been associated with prominent toxicity (both nephrotoxicity and neurotoxicity), which may limit its clinical use [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Swaminathan¹,

Routray²,

Mane³

2022

Cureus

Self Cite

View full text Add to dashboard Cite

The increasing prevalence of antibiotic-resistant pathogens exerts a substantial burden on the healthcare infrastructure worldwide. The World Health Organization (WHO) has declared that multidrug-resistant (MDR) Gram-negative pathogens, especially, carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii, and Pseudomonas aeruginosa as the topmost priority while developing newer antimicrobials. The increasing prevalence of infectious diseases caused by MDR Gram-negative bacteria also poses a challenge when choosing the empiric antimicrobial therapy for seriously ill hospitalized patients. The infections caused by MDR Gram-negative organisms ultimately result in increased mortality, morbidity, prolonged hospital stay, and increased cost of management. To tackle these challenges, newer antimicrobials like ceftazidime-avibactam were explored. The article also discusses the in vitro activity and therapeutic efficacy of ceftazidime-avibactam along with its pharmacokinetic properties and the role it will play in the management of MDR Gram-negative organisms in the Indian setting. Several studies have highlighted the role of early and appropriate antibiotic use in the reduction of mortality in patients with Gram-negative infections. Timely initiation of appropriate antibiotic therapy for serious infections leads to favorable clinical outcomes. Early and appropriate use of ceftazidime-avibactam while treating MDR Gram-negative infections has been associated with improved clinical outcomes. The aim of this review is to highlight the efficacy of ceftazidime-avibactam in the treatment of MDR Gram-negative infections. We have also summarized the information on outcomes achieved by early and appropriate use of ceftazidime-avibactam.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Swaminathan¹,

Routray²,

Mane³

2022

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

Assessment of in vitro activity of ceftazidime/avibactam on carbapenemase‐producing Enterobacterales from Iran: An experimental study

Haeili,

Ghaderi Bavil‐Olyaei

2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsThe prevalence of carbapenemase‐producing Enterobacterales (CPE) continues to increase worldwide. Combination of β‐lactam and novel β‐lactamase inhibitors introduce a revolutionary treatment option for CPE. Ceftazidime/avibactam (CAZ/AVB) has been recently developed for treatment of severe infections caused by multidrug‐resistant bacteria. We aimed to evaluate in vitro activity of CAZ/AVB on a collection of 85 ESBL‐producing‐carbapenemase negative and CPE from Iran.MethodsESBL and carbapenemase production was phenotypically confirmed by combined disk test and modified carbapenem inactivation method respectively. The presence of clinically important carbapenemase encoding genes was examined using PCR. Susceptibility of all isolates to CAZ/AVB was determined using discs containing 30 μg ceftazidime +20 μg avibactam (AVB). Minimum inhibitory concentrations (MICs) of CAZ/AVB in 28 CPE (4 Escherichia coli and 24 Klebsiella pneumoniae) was determined by gradient diffusion method using MIC test strips (0.016−256 mg/L ceftazidime +4 mg/L AVB).ResultsAll phenotypically identified ESBL positive‐carbapenemase negative isolates were found to be susceptible to CAZ/AVB. Among the carbapenem resistant isolates, CAZ/AVB showed potent inhibitory activity against all OXA‐48‐like (MIC ranges 0.125/4−0.75/4 mg/L) and KPC positive isolates (MIC ranges <0.016/4−0.19/4 mg/L). However, AVB could not restore the activity of ceftazdime against isolates producing metallo‐β‐lactamases (MLBs) including VIM, NDM (MIC > 256/4 mg/L) and IMP (MIC > 8/4 mg/L).ConclusionOur data highlighted the excellent in vitro performance of CAZ/AVB against ESBL‐producing and CPE suggesting that this combination can efficiently be used as therapeutic option for management of CPE infections particularly in regions with high prevalence of KPC and/or OXA‐48‐like positive but MBL‐negative Enterobacterales.

show abstract

High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014–2021

Wang,

Lai,

Tsai

et al. 2024

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

In vitro activity of Ceftazidime–Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019

Cited by 28 publications

References 31 publications

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Assessment of in vitro activity of ceftazidime/avibactam on carbapenemase‐producing Enterobacterales from Iran: An experimental study

High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014–2021

Contact Info

Product

Resources

About